BBT Biotech

What BBT Biotech does

BBT Biotech GmbH is a contract service organization (CSO) headquartered in Baesweiler, Germany, that develops and produces active pharmaceutical ingredients (APIs) of biological origin for the international pharmaceutical industry. The company operates GMP-certified manufacturing facilities with fermentation capacity scaled from laboratory (2 L) to commercial (18,000 L) and downstream protein purification capabilities supporting batch sizes from grams to several kilograms. Its product portfolio spans two categories: established thrombolytic proteins (urokinase, streptokinase, aprotinin, and hyaluronidase) addressing global supply gaps for rare APIs, and probiotic/postbiotic microorganisms (E. coli Nissle 1917, E. coli K12, Lactobacillus acidophilus, Saccharomyces boulardii, and others) for pharmaceutical and health-care applications. BBT holds manufacturing authorization under the German Medicines Act (AMG), maintains Drug Master Files (DMFs) for all APIs, and is regularly inspected by German and international health authorities.

The company generates revenue through project-based contract manufacturing engagements and multi-year supply contracts with pharmaceutical manufacturers, complemented by modular service offerings spanning contract analytics, process development, and regulatory affairs support (DMF and eCTD preparation). Customers include pharmaceutical manufacturers requiring GMP-grade APIs for thrombolytic drugs, enzyme therapeutics, and probiotic medications, as well as health-care and feed-additive producers. BBT Biotech is a privately held subsidiary of Pharma-Zentrale, a family-owned pharmaceutical group founded in 1953 in Herdecke, Germany, with no third-party institutional investment. The company employs 11-50 staff and is managed by Detlef Gopon and Jürgen Kirstein as Managing Directors. Distribution is conducted exclusively through direct enterprise engagement with no public pricing, retail presence, or e-commerce channels.

Name

BBT Biotech

Legal name

BBT Biotech GmbH

Website

https://bbt-biotech.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

BBT Biotech GmbH is a German contract service organization that develops and GMP-manufactures biopharmaceutical active ingredients, including thrombolytic proteins (urokinase, streptokinase, aprotinin, hyaluronidase) and probiotic microorganisms, for pharmaceutical manufacturers internationally.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Manufacturing (API)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)

akta.pro secondary industries

Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI)

Keywords

• Contract pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Biopharmaceutical contract services
• GMP fermentation services
• Protein purification services

Headquarters

HQ city

Baesweiler

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing of Active Pharmaceutical Ingredients (APIs): BBT Biotech generates revenue through contract manufacturing of biopharmaceutical APIs including thrombolytic proteins (urokinase, streptokinase), enzyme inhibitors (aprotinin), enzymes (hyaluronidase), and viable probiotic/postbiotic microorganisms. Manufacturing is performed under GMP conditions with batch sizes ranging from grams to kilograms. Revenue is project-based, with long-term supply relationships with pharmaceutical clients for established drug products.
2. Contract Process Development and Laboratory Services: Revenue generated from contract process development, commissioned analytics, and regulatory affairs services. Customers can purchase individual service modules (contract analytics, regulatory document preparation) or a complete package from development through GMP-qualified routine production.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

BBT Biotech is a contract service organization (CSO) that develops, manufactures, and supplies GMP-grade active pharmaceutical ingredients (APIs) of biological origin for the global pharmaceutical industry. Its portfolio spans thrombolytic proteins (urokinase, streptokinase, aprotinin, hyaluronidase) and probiotic/postbiotic microorganisms (E. coli Nissle 1917, Lactobacillus acidophilus, Saccharomyces boulardii, among others), with vertically integrated manufacturing capabilities covering fermentation (up to 18,000 L) through protein purification, lyophilization, in-house QC, and regulatory documentation (DMFs/eCTD).

Product overview

BBT Biotech is a contract service organization and biopharmaceutical manufacturer specializing in active pharmaceutical ingredients (APIs) of biological origin. The company operates two main product lines: (1) Thrombolytic proteins including Streptokinase, Urokinase, Aprotinin, and Hyaluronidase for treating blood clots and inflammatory conditions; and (2) Probiotics and postbiotics including E. coli strains (Nissle 1917, K12), Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus faecalis, Lactobacillus acidophilus, and Saccharomyces boulardii. Services include GMP fermentation (2-18,000 L scale), protein purification via chromatography and ultrafiltration, contract laboratory analytics, and regulatory affairs support including DMF provision. All products are manufactured under GMP conditions with Drug Master Files available for customer registration.

Differentiator

Problem solved

Functional benefit

Products and services

• Streptokinase A proteolytic enzyme derived from hemolytic Streptococci cultures that converts plasminogen to plasmin to dissolve fibrin in blood clots. Supplied as a GMP-grade active pharmaceutical ingredient for treating thromboembolic diseases including myocardial infarction, deep vein thrombosis, and pulmonary embolism. Conforms to the European Pharmacopoeia monograph.
• Urokinase A serine protease isolated from human urine that converts plasminogen to plasmin to dissolve blood clots. Supplied as a GMP-grade active pharmaceutical ingredient for treating pulmonary embolism, myocardial infarction, and preventing catheter clotting. Conforms to European and Japanese Pharmacopoeia monographs.
• Aprotinin A broad-spectrum protease inhibitor that modulates the systemic inflammatory response associated with cardiopulmonary bypass surgery by inhibiting kallikrein and plasmin. Supplied as a GMP-grade active pharmaceutical ingredient for surgical and therapeutic applications.
• Hyaluronidase An enzyme of natural origin derived from bovine testicular preparations that catalyzes degradation of hyaluronic acid, increasing tissue permeability for drug absorption. Used in ophthalmic surgery and treatment of extravasation. Conforms to the European Pharmacopoeia monograph.
• Probiotic and Postbiotic Microorganism APIs (E. coli Nissle 1917, E. coli K12, Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus faecalis, Lactobacillus acidophilus, Saccharomyces boulardii) A portfolio of GMP-manufactured viable probiotic and postbiotic microorganisms including E. coli Nissle 1917 (chronic inflammatory bowel disease), E. coli K12 (production organism), Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus faecalis, Lactobacillus acidophilus (intestinal epithelium attachment, pathogen barrier, lactose digestion), and Saccharomyces boulardii (acute diarrhea treatment and prevention during antibiotic administration). Supplied as active pharmaceutical ingredients for human drug products, health-care products, and feed additives.
• GMP Fermentation Services Contract fermentation development and manufacturing from laboratory scale (2-10 L) through pilot scale (30-750 L) to commercial GMP scale (up to 18,000 L). Supports batch, fed-batch, and continuous fermentation processes for wild-type and recombinant microorganisms, with in-house media development and feed strategies. Available to pharmaceutical industry customers as a standalone service or combined with downstream processing.
• Protein Purification Services Contract downstream processing including medium-scale chromatographic purification with batch sizes from a few grams to several kilograms of purified final product, ultrafiltration processes from 500 mL to 100 L, and lyophilization (freeze-drying) capability. Available to pharmaceutical industry customers as a standalone service or combined with fermentation and regulatory support.
• Laboratory Services (Contract Analytics) Contract laboratory services for microbiological, biochemical, and chemical testing and analysis under GMP standards, including in-process controls, certificates of analysis, and ongoing stability testing. Performed by the company's in-house quality control department in fully equipped laboratories.
• Regulatory Affairs Services Regulatory support for pharmaceutical customers including provision of Drug Master Files (DMFs), preparation of Common Technical Documents (eCTD), validation services, and liaison with health authorities. Supports customer product registrations for APIs manufactured by BBT Biotech.

Quantifiable outcome

• 70% of globally produced insulin is used by 30% of potential insulin users, leaving 70% of patients under-supplied — illustrating the market opportunity for rare APIs like urokinase that BBT addresses.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Lonza: Global leader in biopharmaceutical CDMO services spanning mammalian, microbial, and cell therapy manufacturing at massive scale. Operates broadly in the same biopharma manufacturing services space as BBT but at a vastly larger scale and broader portfolio.
• Siegfried Holding: Swiss CDMO providing contract manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms across small molecules and biologics. Overlaps with BBT in providing contract API manufacturing under GMP conditions to international pharmaceutical clients.
• Boehringer Ingelheim BioXcellence: Large German pharmaceutical company's biopharma CDMO division offering contract manufacturing for biopharmaceuticals including recombinant proteins. Comparable to BBT as a GMP biopharma contract manufacturer with German regulatory oversight and global pharma client base.

Direct peers

• Richter-Helm BioLogics: German biopharmaceutical CDMO with deep expertise in microbial fermentation (E. coli) and protein purification for GMP biologics production. Closely mirrors BBT Biotech's core upstream/downstream fermentation and purification platform.
• Biovian: Nordic biopharma CDMO offering GMP manufacturing of viral vectors, recombinant proteins, and microbial-derived biopharmaceuticals. Comparable to BBT as a specialized microbial fermentation and protein production contract manufacturer serving pharma clients.
• AGC Biologics: Global biopharmaceutical CDMO with microbial and mammalian cell-based GMP manufacturing capabilities. Comparable to BBT in offering contract fermentation and protein purification services, though at substantially larger scale.
• Rentschler Biopharma: German biopharmaceutical CDMO specializing in mammalian cell culture-based recombinant protein production and GMP manufacturing. Directly comparable to BBT Biotech as a mid-sized European contract manufacturer serving pharmaceutical clients with biologics.
• Celonic Group: European biopharmaceutical CDMO specializing in mammalian and microbial GMP bioprocessing and cell banking services. Comparable to BBT in providing contract process development and biomanufacturing services to pharmaceutical clients.
• IDT Biologika: German CDMO focused on vaccines, viral vectors, and biologics GMP manufacturing with integrated fill-finish capabilities. Comparable to BBT in being a German-headquartered biopharma contract manufacturer with established regulatory standing and international pharma customers.

Emerging players

• Novonesis (formerly Chr. Hansen): Global bioscience company producing probiotic cultures, enzymes, and microbial ingredients for food, supplement, and pharmaceutical applications. Comparable to BBT in producing probiotic microorganisms (Lactobacilli, Bifidobacteria) under quality-controlled conditions for health applications.

Market position

Strengths5 records

Weaknesses5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bbt-biotech-gmbh

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BBT Biotech